A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2. (May 2021)

• Record Type: Journal Article
• Authors: Licciardello, Marco P.; Workman, Paul
• Is Part Of: Trends in pharmacological sciences. Volume 42:Number 5(2021)
• Page Start: 313
• Page End: 315
• Publication Date: 2021-05
• Subjects: selective CK2 inhibitor -- protein kinase -- drug target -- cancer -- neurodegenerative diseases -- COVID-19; Pharmacology -- Periodicals; Pharmacology -- trends -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Electronic journals; Periodicals; 615.1
• DOI: 10.1016/j.tips.2021.02.002
• Languages: English
• ISSNs: 0165-6147

Abstract

Abstract : Casein kinase 2 (CK2) is highly expressed in cancer and has been considered a potential therapeutic target. Wells and colleagues developed and characterized the new CK2 inhibitor SGC-CK2-1. Unexpectedly, this potent and highly selective chemical probe does not show broad antiproliferative activity in cancer cells.